In previous preclinical studies, our group found that Mirabegron, a clinical drug, could activate brown adipose tissue and inhibit tumor growth in tumour-bearing mice.Investigators look forward to further evaluating the effect of Mirabegron-mediated brown adipose tissue activation, so as to provide new drug applications for clinical cancer prevention and treatment

Inclusion Criteria:

• Health Volunteers

  1. Sign the informed consent before the study, and fully understand the content, process and possible adverse events.
  2. Both men and women, aged 18-75 years (including the boundary value) .
  3. Body mass index (BMI) is 19.0-26.0 kg/m2 (including the boundary value).

• Tumor patients

  1. Sign the informed consent before the study, and fully understand the content, process and possible adverse events.
  2. Tumor bearing and not in the period of chemotherapy and targeted drug intervention).
  3. Both men and women, aged 18-75 years (including the boundary value) .
  4. Body mass index (BMI) is 19.0-26.0 kg/m2 (including the boundary value).
  5. Proper bone marrow and organ function, as defined below:HB≥80h/L; ANC≥1.5*109/L; PLT≥50*109/L; ALT≤3 upper limit of normal ( ULN ); AST≤3 ULN ; TBIL≤1.5 ULN.
  6. The expected survival is 3 months or more.

Exclusion Criteria:

• Health Volunteers and Tumor patients

  1. A history of tuberculosis infection.
  2. Patients with contraindications to Mirabegron: allergic to Mirabegron or any of its excipients; Patients with poorly controlled severe hypertension(SBP≧180mmHg or/and DBP≧110mmHg).
  3. Women who are pregnant or breastfeeding.
  4. The subject may not be able to complete the study for other reasons or may not be able to participate in the study for other reasons judged by the investigator.